5-苯甲酰基-1,3,6-三甲基-2,4(1H,3H)-嘧啶二酮 | 444058-30-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-苯甲酰基-1,3,6-三甲基-2,4(1H,3H)-嘧啶二酮
• 英文名称: 5-benzoyl-1,3,6-trimethylpyrimidine-2,4(1H, 3H)dione
• 英文别名: 5-benzoyl-1,3,6-trimethylpyrimidine-2,4(1H,3H)-dione；5-benzoyl-1,3,6-trimethylpyrimidine-2,4-dione；5-benzoyl-1,3,6-trimethyluracil；5-benzoyl-1,3,6-trimethyl-2,4(1H,3H)-Pyrimidinedione
• CAS: 444058-30-4
• 化学式: C₁₄H₁₄N₂O₃
• 分子量: 258.277
• InChiKey: YWUIFHYPUIILNG-UHFFFAOYSA-N

物化性质

• 熔点：
  135-136 °C(Solv: isopropanol (67-63-0))
• 沸点：
  372.8±52.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)
• 溶解度：
  >38.7 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  57.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-苯甲酰基-1,3,6-三甲基-2,4(1H,3H)-嘧啶二酮 在 四丙基高钌酸铵 、 溴 、 苄基三甲基氯化铵 、 potassium carbonate 、 N-甲基吗啉氧化物 、 三乙胺 作用下， 以 乙醇 、 氯仿 、 乙腈 为溶剂， 反应 4.42h， 生成 1,3-dimethyl-5-phenyl-8,9-dihydropyrimido[4',5'3,4]pyrrolo[1,2-b]pyridazine-2,4,10(1H,3H,7H)-trione
  参考文献：
  名称：

  TRICYCLIC COMPOUNDS

  摘要：

  本发明提供了一种式I的化合物或其药学上可接受的盐；以及其治疗用途。本发明还提供了一种药理活性剂的组合和一种药物组合物。

  公开号：

  US20140171417A1
• 作为产物：
  描述：

  6-甲基尿嘧啶 在 potassium carbonate 、 zinc(II) oxide 作用下， 以 丙酮 为溶剂， 反应 11.83h， 生成 5-苯甲酰基-1,3,6-三甲基-2,4(1H,3H)-嘧啶二酮
  参考文献：
  名称：

  骨架形形色色的创新[2,1- c ] -1,4-奥氮平和[1,4]-喹喔啉体系的合成

  摘要：

  建立了一种高效，创新的[2,1- c ] -1、4-氧杂氮杂和[1,4]-喹喔啉杂环以及具体的嘧啶基-吡咯基基序的合成方法。最初，通过微波辐射通过乙酰溴甲基嘧啶二酮和邻氨基苯甲醇或邻苯二胺甲基苯甲酸酯之间的分子内碱催化的环化作用来安装吡咯环。此外，通过非常规的Pictet-Spengler反应策略，通过酸催化与多种醛的缩合反应构建了奥沙平和喹喔啉骨架。这项工作的重要方面是建立具有潜在医学价值的新型杂环系统。

  DOI：

  10.1021/acscombsci.5b00093

文献信息

• Pyrano[4,3-d]pyrimidinium salts
  作者：V. V. Kostrub、E. B. Tsupak、Yu. N. Tkachenko、M. A. Shevchenko

  DOI：10.1007/s11172-008-0232-3

  日期：2008.8

  Reactions of 5-aryl- and 5,7-diaryl-1,3-dimethyl-2,4-dioxopyrano[4,3-d]pyrimidinium salts with hydrazine were studied. In the former case, the reaction products were the 6-amino-1,3-dimethyl-2,4-dioxopyrido[4,3-d]pyrimidinium salts. 5,7-Diarylpyrano[4,3-d]pyrimidinium salts were transformed into either the corresponding pyridinium salts or 1H-pyrimido-[5,4-d][1,2]diazepine-2,4(3H,9H)-diones, depending on the hydrazine concentration and the reaction time.

  研究了 5-芳基和 5,7- 二芳基-1,3-二甲基-2,4-二氧代吡喃并[4,3-d]嘧啶鎓盐与肼的反应。前者的反应产物是 6-氨基-1,3-二甲基-2,4-二氧代吡喃并[4,3-d]嘧啶鎓盐。根据肼浓度和反应时间的不同，5,7-二芳基吡喃并[4,3-d]嘧啶鎓盐可转化为相应的吡啶鎓盐或 1H-嘧啶并[5,4-d][1,2]二氮杂卓-2,4(3H,9H)-二酮。
• A Benzannulation Strategy for Rapid Access to Quinazoline-2,4-diones via Oxidative N-Heterocyclic Carbene Catalysis
  作者：Arghya Ghosh、Sayan Shee、Akkattu T. Biju

  DOI：10.1021/acs.orglett.2c00954

  日期：2022.4.15

  benzannulation of enals with suitably substituted pyrimidine-2,4-diones allowing the mild and facile synthesis of functionalized quinazoline-2,4-diones is presented. This oxidative transformation proceeds via the simultaneous generation of dienolates and α,β-unsaturated acylazoliums and follows a vinylogous Michael/aldol/β-lactonization/decarboxylation/oxidation sequence to afford quinazoline-2,4-diones

  介绍了 N-杂环卡宾催化的形式 [4+2] 烯醛与适当取代的 pyrimidine-2,4-diones 的苯环化反应，从而可以温和而简便地合成官能化的 quinazoline-2,4-diones。这种氧化转化通过同时产生二烯醇化物和 α,β-不饱和酰基唑鎓进行，并遵循乙烯基 Michael/aldol/β-内酯化/脱羧/氧化序列，得到喹唑啉-2,4-二酮，包括具有合适取代的轴向手性二酮，在一个操作简单的过程中。此外，取代香豆素作为二烯醇化物前体提供了benzochromen-6-one 衍生物。
• PYRIMIDO-PYRROLO-QUINOXALINEDIONE INHIBITORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND USES THEREFOR
  申请人：Verkman Alan S.

  公开号：US20120208822A1

  公开（公告）日：2012-08-16

  Provided herein are pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity. The compounds, and compositions comprising the compounds, described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, polycystic kidney disease. The compounds may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.

  本文提供了嘧啶并吡咯并喹啉二酮（PPQ）化合物和包含这些化合物的组合物，它们抑制囊性纤维化跨膜传导调节因子（CFTR）介导的离子传输，并且可用于治疗与异常增加的CFTR氯离子通道活性相关的疾病和疾病。本文所述的化合物和包含这些化合物的组合物可用于治疗与异常增加的CFTR活性相关的疾病、疾病和病情后遗症，例如多囊肾病。这些化合物可用于抑制多囊肾病患者的囊肿扩张或预防囊肿的形成。
• PYRIMIDO-PYRROLO-OXAZINE-DIONE COMPOUND INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND USES THEREFOR
  申请人：Verkman Alan S.

  公开号：US20140080821A1

  公开（公告）日：2014-03-20

  Provided herein are benzopyrimido-pyrrolo-oxazine-dione (BPO) compounds and pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity, such as polycystic kidney disease and secretory diarrheas. The compounds and compositions comprising the compounds described herein may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.

  本文提供了苯并嘧啶基吡咯氧噻吩二酮（BPO）化合物和嘧啶基吡咯喹啉二酮（PPQ）化合物以及含有这些化合物的组合物，其抑制囊性纤维化跨膜传导调节因子（CFTR）介导的离子传输，并且可用于治疗与CFTR氯通道活性异常增加相关的疾病和障碍，例如多囊肾病和分泌性腹泻。本文所描述的化合物和组合物可用于抑制在患有多囊肾病的人中囊肿的扩张或预防囊肿的形成。
• Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
  申请人：Verkman Alan S.

  公开号：US08609661B2

  公开（公告）日：2013-12-17

  Provided herein are pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity. The compounds, and compositions comprising the compounds, described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, polycystic kidney disease. The compounds may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.

  本文提供了嘧啶基-吡咯基-喹喔啉二酮（PPQ）化合物和含有这些化合物的组合物，这些化合物能够抑制囊性纤维化跨膜传导调节因子（CFTR）介导的离子转运，并且适用于治疗与CFTR氯离子通道活性异常增加相关的疾病和障碍。本文所描述的化合物和含有这些化合物的组合物适用于治疗与CFTR活性异常增加相关的疾病、障碍和疾病、障碍和病况的后遗症，例如多囊肾病。这些化合物可以用于抑制在患有多囊肾病的人中囊肿的扩张或预防囊肿的形成。